Protein synthesis is energetically the most expensive process in the cell and, not surprisingly, translation rates are tightly regulated predominantly at the level of initiation by modification of the eucaryotic initiation factors (eIFs). In eucaryotes, most mRNAs are translated in a cap-dependent manner. The cap structure, m 7 GpppN (where N is any nucleotide), is present at the 5 0 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b) . The cap structure is bound by the eIF4F complex, which contains the mRNA 5 0 cap-binding protein eIF4E and two other subunits: eIF4A (an ATP-dependent helicase) and eIF4G (a large scaffolding protein), which contains docking sites for the other proteins. eIF4F is directed to the 5 0 end of the mRNA via eIF4E, and acts through eIF4A along with eIF4B to unwind the mRNA 5 0 secondary structure to facilitate ribosome binding (Gingras et al., 1999b) . eIF4G recruits the 40S small ribosomal subunit to the mRNA through the ribosomeassociated eIF3. eIF4E eIF4E was the first translation factor shown to cause malignant transformation when overexpressed in cultured rodent cells (Lazaris-Karatzas et al., 1990) . As eIF4E levels are relatively low in cells as compared to other initiation factors (Hiremath et al., 1985; Duncan et al., 1987) , it was hypothesized that overexpression of eIF4E leads to the deregulation of translational and cellular homeostasis. Importantly, many mRNAs whose translation is enhanced during growth and are implicated in the onset and maintenance of malignancy contain highly structured 5 0 untranslated regions. Thus, increased eIF4E is expected to yield more eIF4F and consequently augmented helicase activity. Indeed, overexpression of eIF4E leads to enhanced translation of many highly structured mRNAs, which are implicated in cell growth, proliferation and survival (reviewed in Mamane et al., 2004) . A link between translation initiation and cancer first became evident in 1990, when overexpression of eIF4E in rodent fibroblasts was shown to cause cellular transformation (LazarisKaratzas et al., 1990) . These studies defined eIF4E as a bona fide oncogene as it cooperates with immortalizing genes (such as E1A or myc) to transform primary embryo fibroblasts (Lazaris-Karatzas and Sonenberg, 1992) . Subsequently, several groups demonstrated that eIF4E levels are substantially elevated in a large number of cancers (colon, breast, bladder, lung, prostate, cervix, gastrointestinal tract, head and neck, Hodgkin's lymphomas and neuroblastomas). More recently, it was shown that the eIF4F complex is required for maintaining breast cancer tumor cell growth . Furthermore, two groups independently demonstrated that eIF4E promotes lymphomagenesis in cooperation with Myc in transgenic mice (Ruggero et al., 2004; Wendel et al., 2004) . Importantly, short interfering RNA (siRNA) knockdown of eIF4E inhibits the growth of several cell lines, including those of head and neck squamous carcinoma cells (Oridate et al., 2005) . eIF4E is thus a potential target for anticancer therapies.
eIF4E levels in the cell are tightly controlled at several levels: (1) Transcription: eIF4E mRNA levels are increased in response to growth factors. eIF4E mRNA transcription is activated by Myc (Schmidt, 2004) . (2) Phosphorylation: eIF4E undergoes phosphorylation at Ser209 by MAP kinase signaling integration kinases 1 and 2 (Mnk1/2) (Fukunaga and Hunter, 1997; Waskiewicz et al., 1997) . eIF4E phosphorylation appears to enhance its transformation potential (Topisirovic et al., 2004) . (3) The translational repressors, 4E-BPs: assembly of the eIF4F complex is inhibited by members of a family of repressors termed the eIF4E-binding proteins (4E-BPs). The mammalian eIF4E-binding proteins, 4E-BP1 (also referred to as PHAS-I for Phosphorylated Heat and Acid-Stable protein regulated by Insulin) and 4E-BP2, were identified in a screen using radiolabelled recombinant eIF4E protein to probe a human placenta expression library (Pause et al., 1994) and by sequencing the complementary DNA (cDNA) clone for PHAS-I (Hu et al., 1994) . A third mammalian homolog, 4E-BP3, was later isolated from a prostate cancer cell line cDNA library (Poulin et al., 1998) . All three isoforms harbor a conserved eIF4E-binding motif Tyr-X-X-X-X-Leu-F (where X is variable and F is a hydrophobic amino acid) and phosphorylation sites critical to the regulation of cap-dependent translation. 4E-BPs and eIF4G share the same eIF4E-binding motif. Structural studies have demonstrated that the eIF4Gs and the 4E-BPs interact through mutually exclusive binding sites on the surface of eIF4E (Marcotrigiano et al., 1999) . Hypophosphorylated 4E-BPs interact strongly with eIF4E, whereas the hyperphosphorylated forms bind weakly (Gingras et al., 1999a (Gingras et al., , 2001 . The phosphorylation of 4E-BP1 upon stimulation (growth factors, mitogens and hormones) occurs at multiple sites and proceeds in a hierarchical manner (first Thr37 and Thr46, then Thr70 and last Ser65) (Gingras et al., 1999a (Gingras et al., , 2001 . Rapamycin treatment inhibits 4E-BP phosphorylation, increases the interaction between eIF4E and 4E-BP, and consequently inhibits cap-dependent translation (Gingras et al., 2001; Grolleau et al., 2002) . Thus, once 4E-BP1 is phosphorylated, it dissociates from eIF4E, hence permitting eIF4G binding and cap-dependent translation to take place.
4E-BPs
The importance of the 4E-BPs in controlling transformation is underscored by their ability to inhibit cell growth and revert the transformed phenotype of eIF4E-overexpressing cells or cells transformed by ras or src genes (Rousseau et al., 1996) . Enhancement of the eIF4E/4E-BP interaction, through the expression of a constitutively active 4E-BP mutant (all phosphorylation sites mutated to Ala), leads to a decrease in cell size and inhibition of cell cycle progression in a manner that mimics rapamycin treatment (Fingar et al., 2002 (Fingar et al., , 2004 . This 4E-BP mutant also slows G1 progression, blocks c-myc-induced transformation (Lynch et al., 2004) and prevents tumor growth . These findings suggest that the ability of rapamycin to inhibit cancer cell growth is in part mediated through the dephosphorylation of 4E-BPs.
S6Ks
Mammalian cells contain two ribosomal protein S6 kinases (S6K1 and S6K2) encoded by two separate genes (Shima et al., 1998) . Both S6Ks are downstream targets of mTOR (reviewed in Hay and Sonenberg, 2004) . It was thought that S6Ks are critical for translation of mRNAs that bear a terminal oligo pyrimidine (TOP) sequence in their 5 0 UTR (reviewed in Meyuhas, 2000) . However, this model of translational regulation has recently been disproved, as in cells lacking both S6K1 and S6K2, TOP mRNA translation is intact and remains rapamycin-sensitive (Pende et al., 2004) . This agrees with earlier results showing that amino acid dependent or mitogenic-stimulated translation of TOP mRNAs is dependent on PI3K-mediated signaling, but requires neither S6K1 nor ribosomal protein S6 phosphorylation (Tang et al., 2001; Stolovich et al., 2002) . A role for the S6 kinases in controlling the cell size has been suggested as their deletion results in smaller animals (Pende et al., 2004) . Recent studies have addressed the specific role of S6K1 in tumor invasiveness, motility and angiogenesis (Skinner et al., 2004; Zhou and Wong, 2006) . Zhou and Wong (2006) demonstrated a role for S6K1 in the motility and invasiveness phenotype activated by hepatocyte growth factor (HGF). Treatment of ovarian cancer cells with HGF is associated with increased S6K1 phosphorylation and increased motility, which are blocked by LY294002 and wortmannin (specific phosphatidylinositol 3 0 -kinase (PI3K) inhibitors). A significant role for S6K1 in cell invasion is further supported by the observation that expression of constitutively active S6K1 increases the invasiveness of ovarian cancer cells, which can be explained by elevated amounts of matrix metalloproteinases (MMPs) (Zhou and Wong, 2006) . Increased expression of MMPs in human ovarian cancers is directly associated with their invasive and metastatic potential and poor prognosis of the disease (Schmalfeldt et al., 2001) . S6K1 stimulates angiogenesis by increasing vascular endothelial growth factor (VEGF) production. Consistent with this, S6K1 overexpression reversed the LY294002-mediated inhibition of VEGF expression (Skinner et al., 2004) . VEGF is essential for both physiological and pathological angiogenesis in cancer, such as ovarian cancers (Paley et al., 1997; Wang et al., 2006) . Activation of PI3K signaling mediates VEGF expression through the hypoxia-inducible factor 1a (HIF-1a) in human ovarian cancer cells (Skinner et al., 2004) . Taken together, these data suggest an important role for S6K1 in coordinating key processes associated with tumor invasiveness and angiogenesis in ovarian cancer.
A new connection between the mTOR/S6K1 pathway and translation initiation has been demonstrated recently (Holz et al., 2005; Peterson and Sabatini, 2005) . In the absence of extracellular stimuli such as growth factors and nutrients, S6K1 is associated with eIF3 ( Figure 1 ). Upon addition of growth factors or nutrients, the mTOR/raptor is recruited to eIF3 to phosphorylate S6K1 and 4E-BP1 (Figure 1 ). Phosphorylation of S6K1 at T389 leads to its dissociation from eIF3. T389-phosphorylated S6K1 binds to phosphoinositide-dependent kinase 1 (PDK1), which phosphorylates S6K1 at T229. The fully activated S6K1 then phosphorylates eIF4B and S6. Phosphorylation of eIF4B by S6K1 at S422 promotes its association with eIF3 (Holz et al., 2005; Shahbazian et al., 2006) . mTOR, translation initiation and cancer Y Mamane et al eIF4B undergoes phosphorylation not only by the PI3K/mTOR pathway, but also by the ERK 1/2 MAPK pathway . The interaction of mTOR with eIF3 also augments the association between eIF3 and eIF4G (Harris et al., 2006) . All of these molecular interactions cooperate to enhance translation initiation complex formation and cap-dependent translation (Figure 1 ).
Other eIFs
Other translation initiation factors might be implicated in tumorigenesis: eIF4GI is overexpressed in squamous cell lung carcinomas (Brass et al., 1997; Keiper et al., 1999; Bauer et al., 2001 Bauer et al., , 2002 , and eIF4GI transforms NIH 3T3 cells (Fukuchi-Shimogori et al., 1997) . eIF4GI is a downstream target of mTOR as rapamycin treatment inhibits its phosphorylation (Raught et al., 2000) . However, it is not known whether mTOR phosphorylates eIF4GI directly. eIF4A is overexpressed in human melanoma cells and in primary hepatocellular carcinomas (Eberle et al., 1997; Shuda et al., 2000) . eIF3 has also been implicated in cellular transformation in breast, liver and prostate cancers (Okamoto et al., 2003; Savinainen et al., 2004) . (Figure 2) . mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the 4E-BPs (Gingras et al., 2001; Jacinto and Hall, 2003; Kim et al., 2003; Ruggero and Pandolfi, 2003; Kim and Sabatini, 2004) . Hyperphosphorylated 4E-BPs are released from eIF4E resulting in enhanced cap-dependent translation.
mTOR functions by integrating extracellular signals (mitogens, growth factors and hormones) with aminoacid availability and intracellular energy status to control translation rates and additional metabolic processes (Hay and Sonenberg, 2004) (Figure 2 ). mTOR has received considerable attention, as rapamycin (Rapamune) is a specific inhibitor of mTOR activity (for review see Hay and Sonenberg, 2004; De Virgilio and Loewith, 2006) . Rapamycin is an immunosuppressant Figure 1 Activation of translation initiation by mTOR. Nutrients, hormones and growth factors activate the mTOR, which forms a complex with other proteins including raptor and LST8/GbL. mTOR phosphorylates two major targets: 4E-BPs and S6Ks (most of the work has been performed with 4E-BP1 and S6K1). Phosphorylated 4E-BP is released from eIF4E. In the absence of extracellular stimuli, S6K1 is associated with eIF3. In response to extracellular stimuli, such as growth factors or nutrients, the mTOR complex is recruited to eIF3 to phosphorylate S6K1 and 4E-BP1. Phosphorylation and activation of S6K1 leads to its dissociation from eIF3. Activated S6K1 then phosphorylates eIF4B and S6. Phosphorylation of eIF4B at S422 promotes its association with eIF3. mTOR also stimulates the association between eIF3 and eIF4G. These multiple interactions culminate in enhanced cap-dependent translation (see text for details and references).
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and is used in clinical applications such as transplantation and restenosis (Young and Nickerson-Nutter, 2005) . Rapamycin exerts its biological effect by binding to . This complex then binds to mTOR, inhibits its kinase activity and subsequent signaling to downstream targets, such as 4E-BP and S6K, is abrogated (reviewed in Hay and Sonenberg, 2004) (Figure 2 Akt is phosphorylated by PDK1 and an mTOR complex that contains LST8/GbL and rictor. Akt phosphorylates TSC2 and destabilizes the TSC1/2 complex, thus promoting the activation of mTOR by Rheb. Energy status (the AMP/ATP ratio) and LKB1 modulate AMPK activity. REDD1, induced upon hypoxia, acts through the TSC1/2 complex to inhibit mTOR. Amino acids signal through Vps34 (a class III PI3K) to mTOR possibly by promoting the formation of the Rheb/mTOR complex (the question marks indicate that it is not clear whether Vps34 acts through Rheb or mTOR). The mTOR complex with raptor and LST8/GbL mediates the phosphorylation of 4E-BP1, S6K1 and eIF4G. Once activated, S6K1 phosphorylates ribosomal protein S6 and eIF4B. Pharmacological inhibition of PI3K (wortmannin or LY294002) and mTOR (rapamycin or its analogs) or activation of AMPK (by increased AMP/ATP ratio, metformin or AICAR) is indicated.

Translation initiation and apoptosis
Translational control has important implications for cell growth, cell survival and apoptosis. Synthesis of proteins that have pro-or anti-apoptotic functions can alter the balance between cell survival and cell death. eIF4E plays an important role in the control of this balance Clemens, 2001; Dua et al., 2001; Li et al., 2003 Li et al., , 2004 . eIF4E overexpression compensates for serum/growth factor deprivation by promoting the survival of NIH 3T3 cells (Polunovsky et al., 1996) . Furthermore, high levels of eIF4E rescue rat embryo fibroblasts ectopically expressing c-Myc from genotoxic and non-genotoxic cytostatic drugs . Increased levels of cyclin D1 due to eIF4E overexpression could be a major downstream effector in this antiapoptotic mechanism . eIF4E also rescues cells from Myc-dependent apoptosis, by inhibiting mitochondrial cytochrome c release through an increase in Bcl-X L mRNA translation (Li et al., 2003) . Indeed, eIF4E counteracts c-Myc induced cell death in transgenic mice (Ruggero et al., 2004) . eIF4E also blocks endoplasmic reticulum-and p53-mediated apoptosis Mungamuri et al., 2006) . mTOR controls cell survival (Edinger and Thompson, 2002; Mungamuri et al., 2006) . eIF4E could serve as an important downstream effector of mTOR in the control of cell survival through the 4E-BPs. The 4E-BPs promote apoptosis: ectopic expression of 4E-BP1 induces apoptosis in both normal and Ras-transformed fibroblasts Li et al., 2002) . 4E-BP1 undergoes caspase-dependent cleavage in apoptotic cells. The cleaved 4E-BP1 binds strongly to eIF4E, fails to become sufficiently phosphorylated and thus inhibits cap-dependent translation (Tee and Proud, 2002; Proud, 2005) . Furthermore, a non-phosphorylatable mutant of 4E-BP1 mutant, in which the critical phosphorylation site threonine and serine amino acids were mutated to alanines, sensitizes multiple myeloma cells to dexamethasone-induced apoptosis (Yan et al., 2006) . It is noteworthy that the mRNAs encoding several protein inhibitors of apoptosis (XIAP, c-IAP1 and BCl-2) and pro-apoptotic proteins (c-Myc, APAF-1) contain internal ribosomal entry sites (IRES), which serve to sustain translation during apoptosis, when cap-dependent expression is suppressed (reviewed in Proud, 2004) .
Because the 4E-BPs are important targets of mTOR, they play a significant role in mediating rapamycin sensitivity. The 4E-BPs sensitize cells to rapamycinmediated apoptosis in Ras-overexpressing cells . Rapamycin-resistant rhabdomyosarcoma cells (Dilling et al., 2002) express low levels of 4E-BP1, do not exhibit rapamycin-inducible c-Jun NH 2 -terminal kinase (JNK) activation and are resistant to apoptosis (Huang et al., 2003) . This phenotype can be rescued by 4E-BP1 overexpression or mimicked by 4E-BP1 knockdown in rapamycinsensitive cells. Rapamycin induced cell death by JNK activation occurs only in the absence of p53 (Huang et al., 2003) . Thus, rapamycin induces apoptosis only in cells lacking functional p53. These results may be useful in the development of tumor-selective therapy with rapamycin.
S6K1 is another mTOR target that could play a role in the apoptosis resistance of cancer cells. TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a mediator of anti-tumor drug activity, and a promising target for the treatment of cancer (Wang and El-Deiry, 2003) . However, a significant percentage of human tumors are insensitive to TRAIL-induced apoptosis (Wang and El-Deiry, 2003) . In a recent study, Panner et al. (Panner et al., 2005 (Panner et al., , 2006 reported that resistance to TRAIL-induced apoptosis is associated with reduced expression of the anti-apoptotic FLICE like inhibitory proteins (FLIP S ) and decreased S6K phosphorylation. FLIP S mRNA was poorly translated as it sedimented with light polysomes in TRAILsensitive glioblastomas, but co-sedimented with heavy polysomes in TRAIL-insensitive glioblastomas, thus indicating that FLIP S expression is regulated translationally (Panner et al., 2005) . Importantly, FLIP S mRNA distribution in polysomes correlated with the cell sensitivity to TRAIL-induced apoptosis (Panner et al., 2005) . Accordingly, rapamycin treatment or siRNA-mediated knockdown of S6K1 in TRAILinsensitive cells led to decreased translation of the FLIP S mRNA and re-sensitized cells to apoptosis. Conversely, overexpression of S6K1 in TRAIL-sensitive cells led to augmented translation of the FLIP S mRNA and protected cells from TRAIL-induced apoptosis (Panner et al., 2005) . These results demonstrate that S6K1 activation in glioblastoma causes a redistribution of the FLIP S mRNA to heavier polysomal fractions, increasing FLIP S protein levels and TRAIL-mediated resistance.
Other eIFs are also involved in cell survival. p97/NAT-1/DAP5, a member of the eIF4G family, which acts as a general translational inhibitor (Imataka et al., 1997; Yamanaka et al., 1997) , but stimulates translation of its own mRNA (Henis-Korenblit et al., 2002) , also plays a role in apoptosis. When cleaved by caspases, p97/NAT-1/ DAP5 promotes the translation of IRES-dependent mRNAs whose products are involved in apoptosis such as those encoding for c-Myc, XIAP, APAF-1 (Henis- Korenblit et al., 2002) and HIAP2 (Warnakulasuriyarachchi et al., 2004) . A recent study on eIF3f, the p47 subunit of the multi-subunit eIF3 complex, showed that it exhibits pro-apoptotic properties, as its overexpression inhibited cell proliferation and induced apoptosis in melanoma and pancreatic cancer cells .
Summary
Translational control plays a major role in regulating gene expression, which is crucial for cell growth, survival and cellular homeostasis. The major cellular signaling mTOR, translation initiation and cancer Y Mamane et al pathways impinge on the translational machinery by phosphorylating a large number of translation initiation factors. The PI3K/Akt/mTOR signaling pathway is intimately implicated in cancer development and progression, inasmuch as many of its components are either mutated or amplified in human cancers. These changes in the PI3K/Akt/mTOR signaling pathway deregulate translation. Understanding the molecular basis of translational deregulation in cancer will hopefully contribute to the development of novel anticancer therapeutic strategies.
